What the U.S. Can Learn From the Countries Rethinking Menopause Care

Menopause 3.0:

What the U.S. Can Learn From the Countries Rethinking Menopause Care

For a life stage experienced by roughly half the population, menopause has spent an impressive amount of time being treated like a niche medical issue.

Hot flashes? Normal.

Brain fog? Getting older.

Sleep problems? Stress.

Weight changes? Try harder.

Mood changes? Also stress.

For millions of women, the message was essentially: Welcome to midlife. Good luck out there.

That is finally changing.

Around the world, menopause is moving from the margins of healthcare into national health policy, clinical guidelines, research agendas and primary care. And when you compare what is happening in Australia, the United Kingdom and the United States, an interesting pattern emerges.

The next big advance in menopause care may not simply be a new treatment. It may be better personalization.

Three countries, three very different approaches

The U.S., U.K. and Australia all have sophisticated healthcare and research ecosystems. But they have taken notably different approaches to menopause.

The simplest way to think about it is this:

	Australia	U.K.	U.S.
National menopause strategy	Strong and rapidly expanding	Strong and established	Fragmented
Clinical guidelines	National guidelines in development	Mature NICE guidance	Multiple professional guidelines
Primary care integration	Dedicated Medicare menopause assessments	Increasing NHS integration	Varies significantly
HRT access	National access initiatives	Integrated into NHS guidance	Available, but access varies
Non-hormonal options	Part of broader menopause management	Explicitly incorporated into guidance	Available, but decentralized
Provider education	National investment underway	National strategy priority	Highly variable
Research	Growing dedicated investment	Strong public research infrastructure	Major historic research strength
Personalization	Emerging	Clinically individualized	Emerging

The chart doesn't really identify a "winner."Instead, it reveals three different strengths.

The U.K. has become particularly good at turning evidence into clinical guidance. Australia is aggressively turning menopause into an organized care pathway. The United States remains an extraordinary engine for research, therapeutics and healthcare innovation, but care delivery is much more fragmented.

And all three leave an intriguing question largely unanswered:

What happens when menopause care becomes more biologically personalized?

The U.K.: Make menopause part of medicine

One of the most interesting things the U.K. has done is surprisingly straightforward.

It listened to women.

England's Women's Health Strategy followed a public consultation that received almost 100,000 responses. Menopause emerged as a significant concern, particularly among women ages 40 to 59. Only 9% of respondents reported feeling that they had enough information about menopause.

The resulting strategy addressed menopause as more than a prescription issue. It included research, education, information, healthcare services and women's experiences.

The U.K.'s NICE guidance similarly reflects a broader view of treatment. Hormone replacement therapy is an important option, but guidance also addresses menopause-specific cognitive behavioral therapy, treatment of genitourinary symptoms and non-hormonal pharmacological options in appropriate circumstances.

The message is essentially that there isn't one menopause experience, so there shouldn't be one menopause conversation. That seems obvious…sadly, healthcare occasionally takes the scenic route to obvious.

Australia: Build an actual menopause care pathway

Australia may be the most interesting country to watch right now because it is attacking menopause from several directions simultaneously.

Research. Provider education. Public awareness. Clinical guidelines. Treatment access. Reimbursement.

Most notably, Australia introduced dedicated Medicare menopause and perimenopause health assessments in November 2025. These assessments can address physical, psychological and social dimensions of menopause and help develop an appropriate management plan.

That's a meaningful shift.

Instead of expecting a woman to identify menopause herself, find the right specialist, determine which symptoms are relevant and navigate treatment options on her own, the healthcare system begins to create an actual place for the conversation to happen.

Australia is also developing national clinical guidelines for perimenopause and menopause and investing in menopause-specific research and decision-support resources. That's the difference between having treatments and having a system of care.

The United States: Scientific powerhouse, fragmented experience

It would be easy to look at Australia and the U.K. and conclude that America simply ignored menopause.

That's not accurate.

The United States has been responsible for some of the most consequential menopause research ever conducted.

The Women's Health Initiative enrolled more than 161,000 women and fundamentally changed our understanding of postmenopausal health and hormone therapy. It also helped trigger one of the most complicated chapters in modern women's health.

Early interpretations of hormone therapy findings contributed to widespread concern about HRT. Subsequent research and analysis have produced a more nuanced understanding of how factors such as age, timing, health history and individual risk affect the benefit-risk discussion.

The U.S. also continues to innovate in both hormonal and non-hormonal treatments. So America's problem isn't a lack of science, it's consistency.

A woman receiving menopause care from a highly trained specialist at a leading medical center can have an entirely different experience from someone whose primary care clinician has limited menopause training. Same country, same life stage, very different care.

The evolution of menopause care

Looking across these three countries suggests that menopause care has been progressing through distinct stages.

Menopause 1.0: Recognition

First came the basic acknowledgment that menopause symptoms are real, varied and capable of meaningfully affecting health and quality of life. An embarrassingly low bar, perhaps but still progress.

Menopause 2.0: Better access to treatment

The next stage has been expanding the conversation around treatment. HRT can be highly effective and appropriate for many women while other women may need or prefer non-hormonal options.

Some benefit from interventions targeting sleep, mental health, genitourinary symptoms, lifestyle factors or other specific concerns. Modern menopause medicine increasingly asks, "Which options are appropriate for this woman?" rather than "Does she get HRT or not?" That's an enormous improvement, but it leads to another question.

Menopause 3.0: Personalization

Why can two women of similar ages experience the menopause transition so differently? Why does one struggle primarily with sleep while another experiences significant vasomotor symptoms? Why might similar lifestyle interventions produce very different experiences? Why do treatment decisions require so much individualization in the first place?

Part of the answer is obvious: We're biologically different. And that's where the next era of menopause care gets interesting.

Your hormone levels are a snapshot. Your biology has a longer story.

Hormone testing can provide valuable information about what is happening physiologically at a particular point in time.

But hormones fluctuate.

The underlying biology influencing how our bodies respond to hormonal change is more complex.

Genetics can offer another layer of information about biological pathways associated with processes such as hormone metabolism, stress response, sleep, nutrient metabolism and other systems relevant to health.

That doesn't mean DNA predicts exactly how someone will experience menopause. And it certainly doesn't mean a DNA test should determine whether someone receives HRT or another treatment.

Instead, genetics can potentially provide additional biological context.

Where Rephase Health fits

Rephase Health was built around the simple idea that women deserve more than generic explanations for a deeply individual biological transition.

Rephase uses DNA-based insights to help women better understand aspects of their underlying biology that may provide context around their midlife experience.

The goal isn't to diagnose menopause or to replace laboratory testing. It's also not to tell a clinician how to practice medicine. It's to add another layer to the conversation.

Traditional clinical information can help answer, “What's happening right now?”

Rephase explores another question. “What can my underlying biology help me understand about myself?”

Behind Rephase is the EndoDNA + BIOS platform, which is designed to translate complex genetic and biological information into clearer, more useful insights. That becomes especially interesting as healthcare moves toward longitudinal, personalized care rather than one-size-fits-all recommendations.

The future probably isn't HRT versus "natural"

For too long, menopause conversations have been forced into opposing camps.

Hormones versus no hormones. Conventional medicine versus wellness. Prescription versus lifestyle.

Those binaries aren't particularly helpful. The better question is, “What does the evidence support for this individual person?” Sometimes that may include hormone therapy. Sometimes non-hormonal medication. Sometimes behavioral or lifestyle interventions.Often it may involve several approaches.

Over time, we believe better biological information can add useful context to those decisions.That's not a rejection of evidence-based menopause medicine, it's where evidence-based medicine has been heading all along..Toward the individual.

What Australia and the U.K. are getting right

The biggest lesson from the international comparison isn't that America needs to copy another country's healthcare system. It's that good menopause care requires more than having good treatments available. It requires a connected ecosystem: Research that asks better questions, clinical guidelines that translate research into practice, providers who are educated about menopause, healthcare systems that make care accessible, patients who are given understandable information, multiple evidence-based treatment options, and ultimately, enough information to personalize care around the individual.

Australia is investing heavily in building that ecosystem.

The U.K. has created increasingly sophisticated clinical infrastructure around it.

The U.S. continues to push research and innovation forward.

The opportunity now is to connect those lessons.

Menopause isn't generic. Care shouldn't be either.

The first revolution in menopause care was getting women to talk about it. The second was getting medicine to take it seriously. The third may be understanding just how individual the experience really is.

It’s not replacing physicians with algorithms or proven treatments with genetic reports. It’s not promising that DNA holds some magical answer to every hot flash, sleepless night or unexplained change.

Rather it’s more context, better questions, more informed conversations and care designed around the person experiencing it.

That's the future we think is worth building.